Abstract: A graphical system is disclosed comprising: a lofted graph comprising a one or more slices arranged on a path. Said one or more slices connected to one another by lofting them together. Each of said one or more slices separated from one another by a cycle distance. A one or more period values each associated with a one or more cycle values. Said one or more slices representing a one or more values at said cycle value. Said one or more values comprising a datum at said cycle value.

Abstract: A breakaway rope holder comprising: a breakaway rope holder comprising a loop having a first end and a second end, a body having a rope bore. The rope bore is capable of receiving a first end of a rope. The first end of the loop attaches to the body. The second end of the loop releaseably attaches to the body.

Abstract: This invention is a spring-powered bolt launcher to facilitate tugging wire or cable between two locations; typically, the locations are in low light levels, are remote by about 10-20 meters and are above a suspended ceiling in a building. The present launcher includes a unique hoop-rocker-slide mechanism to assure safe, controlled and precise launching of a bolt from the origin toward the target. The present launcher system also includes unique combinations of spliced-sequential tethers capable of accurate placement even over ranges of 20-30 meters. The present launcher system is also disclosed in the form of field-configurable kits which are carried in a portable case including a group of selectable component trays. Once the bolt is attached to cable to be pulled, the tether allows the operator to tug cable to be connected between the locations.

Abstract: A test driver generator is provided for generating test drivers. The test driver generator receives test expressions designating execution sequences of test functions of software interfaces and corresponding attribute value specifications for the designated test functions' parameter attributes. Each test expression designating a number of test functions to be executed in a certain sequence, and each corresponding attribute value specification specifies selected attribute values of the test functions' parameter attributes. For each test expression and corresponding attribute value specifications of a software interface, the test driver generator, in response, generates a test driver that can execute the specified test functions in the designated order with all combinations of the selected attribute values of the test functions' parameter attributes.

Abstract: A test driver generator is provided for generating test drivers from test function designations and attribute value specifications of software interfaces. For each set of designations and specifications for a software interface, the test driver generator generates a test driver. The test driver executes the designated test functions selectively based on selections provided at its invocation, using the selected combinations of attribute values specified. For each selected combination of attribute values of each selected test function, the test driver creates the test data for the particular combination of attribute values, executes the selected test function and deletes the created test data. The test driver repeats the process for all selected combinations of attribute values of all selected test functions.

Abstract: An auto-checking testing funtion generator is provided for generating auto-checking testing functions for procedures of a software interface from a formal specification specifying the procedures. The procedures are specified with procedure semantic expressions identifying the procedures and specifying their arguments, returning results, raisable exceptions, exceptional and normal terminations. Each exception or normal termination specifies the correct post-execution exception or normal termination state for the procedure given a particular pre-execution state. The procedure semantic expressions are boolean expressions constructed using comparison and boolean operators, calls to the procedure, auxiliary and special functions. The auxiliary functions are user supplied, and the special functions are supplied by the auto-checking testing funtion generator. An auto-checking testing funtion is generated for each procedure.

Abstract: Compounds are described of the formula (1) ##STR1## where: R.sup.1 is a hydrogen atom or a methyl group;X is cis or trans --CH.dbd.CH-- or --CH.sub.2 CH.sub.2 --, m is 2, 3 or 4 and n is 1; or X is trans --CH.dbd.CH--, m is zero and n is 3;Y is a saturated heterocyclic amino group;Alk is a C.sub.1-5 alkyl chain;l is zero or 1;p is zero, 1, 2, 3 or 4;R.sup.2 is a hydroxyl group or a group selected from --OCOR.sup.3, --CO.sub.2 R.sup.3, CONR.sup.3 R.sup.4, --SO.sub.2 NR.sup.3 R.sup.4, --NHCOR.sup.3, --NHSO.sub.2 R.sup.5, --SO.sub.2 R.sup.5, --SR.sup.5, --NR.sup.3 R.sup.4, --COR.sup.5, --NHCONR.sup.3 R.sup.4 and --NHCSNH.sub.2 ; and their physiologically acceptable salts, solvates and cyclodextrin complexes.These compounds inhibit blood platelet aggregation, bronchoconstriction and vasoconstriction and may be formulated for use as antithrombotic agents.

Abstract: The invention provides compounds of the general formula ##STR1## and physiologically acceptable salts and hydrates thereof, in which one of R.sub.1 and R.sub.2 represents hydrogen, halogen or a C.sub.1-4 alkyl group which may be optionally substituted by hydroxy or C.sub.1-4 alkoxy, and the other represents the group R.sub.4 R.sub.5 NAlk-- in which Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms;R.sub.3, which may be in either the 2 or 3-position, represents the ##STR2## where X represents --CH.sub.2 --, --O-- or --S--; n represents zero, 1 or 2;m represents 2, 3 or 4; andR.sub.7 represents hydrogen, alkyl, alkenyl, aralkyl, or C.sub.2-6 alkyl substituted by hydroxy or alkoxy; andR.sub.8 represents hydrogen, alkyl, alkenyl, aralkyl, hydroxyalkyl, acyloxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkyloxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxy or alkoxy, or the group NR.sub.10 R.sub.11 ; with the provisos thatwhere R.sub.2 represents the group R.sub.4 R.sub.

Abstract: The invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which the substituents are defined in the detailed description.The compounds show pharmaceutical activity as selective histamine H.sub.2 -antagonists.

Abstract: This invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts and hydrates thereof, in which R.sub.1 represents a hydrogen atom or an alkyl, alkanoyl, aroyl or trifluoroalkyl group;R.sub.2 represents a hydrogen atom or an alkyl or alkenyl group or C.sub.2-6 alkyl group substituted by a hydroxy or alkoxy group;X represents a sulphur atom or NH;Y represents an oxygen or sulphur atom or a bond;m represents 1, 2 or 3; andn represents 2, 3 or 4.The compounds show pharmacological activity as selective histamine H.sub.2 -antagonists.

Abstract: The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in whichQ represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4- positions:Z represents one of the groups ##STR2## where X represents NCN, NSO.sub.2 Methyl, NSO.sub.2 Phenyl or CHNO.sub.2. The compounds show pharmacological activity as selective histamine H.sub.2 -antagonists.

Abstract: The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, which show pharmacological activity as selective histamine H.sub.2 -antagonists.

Abstract: Compounds of the formula (I) ##STR1## in which R.sub.1 and R.sub.2 each may represent hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, or alkyl, substituted by hydroxy, C.sub.1-3 alkoxy, amino, C.sub.1-3 alkylamino or di-C.sub.1-3 alkylamino or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form an alicyclic heterocyclic ring which may be unsubstituted or may be substituted by one or more C.sub.1-3 alkyl groups or a hydroxy group and/or may contain another heteroatom are described.Alk is a straight lower alkylene chain,Q is a furan or thiophen ring, the furan ring optionally bearing a further substituent R.sub.5 adjacent to the group R.sub.1 R.sub.2 NAlk-- or Q represents a benzene ring.R.sub.5 represents halogen or C.sub.1-3 alkyl which may be substituted by a hydroxy or C.sub.1-3 alkoxy group;X represents --CH.sub.2 --, --O-- or --S--;n represents zero or 1;m represents 2, 3 or 4;Y represents .dbd.O or .dbd.S;R.sub.3 represents hydrogen in which case R.sub.

Abstract: The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, and hydrates thereof. The substituents are defined in the specification.The compounds show pharmacological activity as selective histamine H.sub.2 -antagonists.

Abstract: The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts or hydrates thereof, in which the substituents are defined later in the specification.The compounds show pharmacological activity as selective histamine H.sub.2 -antagonists.

Abstract: The invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof in which the substituents are defined in the specification.The compounds of formula (I) show pharmacologically activity as selective histamine H.sub.2 -antagonists.

Abstract: Compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof have been found to show pharmacological activity as selective histamine H.sub.2 -antagonists. The substituents in the compounds of formula (I) are defined in the main body of the disclosure.

Abstract: Compounds of general formula (I) ##STR1## and physiologically acceptable salts and hydrates thereof in which R.sub.1 and R.sub.2 each represent methyl groups or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexamethylenimino group;R.sub.3 represents hydrogen or methyl;Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms;R.sub.4 represents a hydrogen atom and R.sub.5 represents a C.sub.1-4 alkyl group; or R.sub.4 and R.sub.5 together with the atoms to which they are attached form a tetrahydropyranyl ring; andeither n is zero, X is oxygen, m is 3 or 4, and Q is a benzene ring linked through the 1- and 3- positions;or n is 1, X is sulphur, m is 2, and Q is a furan ring linked through the 2- and 5- positions with optionally a methyl substituent on the carbon atom adjacent to the group R.sub.1 R.sub.2 NCH.sub.2, or Q is a thiophene ring linked through the 2- and 4- positions with the group R.sub.1 R.sub.2 NCH.sub.

Abstract: The invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in whichR.sub.1 and R.sub.2, which may be the same or different, each represent hydrogen, C.sub.1-10 alkyl, cycloalkyl, alkenyl, aralkyl, trifluoroalkyl, heteroaralkyl, or alkyl substituted by hydroxy, alkoxy, amino, alkylamino, dialkyamino or cycloalkyl, or R.sub.1 and R.sub.2 may together with the nitrogen atom to which they are attached form a 5 to 10 membered ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C.sub.1-3 alkyl groups, or a hydroxy group and/or may contain another heteroatom selected from oxygen and sulphur;Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms and is attached to the cyclohexadiene ring at either the 4- or 5- position;X represents --CH.sub.2 or --O--;m represents 2, 3, 4 or 5 and when X is --O-- the chain (CH.sub.2).sub.

Abstract: Compounds of the general formula ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof are disclosed, in whichR.sub.1 and R.sub.2, which may be the same or different, represent hydrogen, lower alkyl, cycloalkyl, aralkyl or lower alkenyl groups, which alkyl groups may be interrupted by an oxygen atom or a group ##STR2## in which R.sub.4 represents hydrogen or lower alkyl; or R.sub.1 and R.sub.2 may, together with the nitrogen atom to which they are attached form a heterocyclic ring which may contain other hetero functions selected from --O-- and ##STR3## R.sub.3 represents hydrogen, lower alkyl, lower alkenyl or alkoxyalkyl; X represents --O--, --S-- or --CH.sub.2 --;Y represents .dbd.S, .dbd.O, .dbd.NR.sub.5 or .dbd.CHR.sub.6 ;in which R.sub.5 is hydrogen, nitro, cyano, lower alkyl, aryl, alkylsulphonyl or arylsulphonyl and R.sub.6 represents nitro, alkylsulphonyl or arylsulphonyl;m is an integer from 2 to 4 inclusive;n is 1 or 2 or, when X is S or CH.sub.